View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 26, 2016

Eiger doses first patient in Phase II Ultra trial of ubenimex to treat secondary lymphedema

US-based biopharmaceutical company Eiger has dosed the first patient in the Phase II Ultra trial of ubenimex to treat secondary lymphedema of the lower limbs.

US-based biopharmaceutical company Eiger has dosed the first patient in the Phase II Ultra trial of ubenimex to treat secondary lymphedema of the lower limbs.

Ubenimex is a well-characterised, oral, small-molecule that inhibits leukotriene A4 hydrolase (LTA4H), an enzyme instrumental in the formation of the pro-inflammatory mediator LTB4, which causes tissue inflammation and impaired lymphatic function.

The multi-centre, randomised, double-blind, placebo-controlled Phase II trial is planning to involve about 40 patients with secondary lymphedema of the lower limbs and are undergoing physical therapies.

During the trial, patients will be randomised on a 1:1 ratio and administered with ubenimex or matching placebo orally for a duration of 24 weeks.

"The ULTRA study is designed to explore a novel approach to the treatment of secondary lymphedema by blocking the production of LTB4."

Eiger chief medical officer Joanne Quan said: "Lymphedema can have long-lasting deleterious effects and significantly impact quality of life.

“There is no FDA approved pharmacologic treatment. Patients must currently rely on physical therapies such as manual lymph drainage and compression garments for relief.

"The ULTRA study is designed to explore a novel approach to the treatment of secondary lymphedema by blocking the production of LTB4.

“This approach has the potential to lessen the effects of this serious and debilitating disease and provide a convenient treatment option for patients."

The trial will examine the clinical, biomarker, histologic and patient-reported results following the administration of ubenimex.

Ubenimex has pharmacologically inhibited LTB4, which resulted to lymphatic repair and reversed lymphedema disease in animals.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena